Tumor cells utilize inappropriate epithelial-mesenchymal transition (EMT) mechanisms during the invasive process. It is becoming increasingly clear that
estradiol (E2) induces
breast cancer cell progression and enhances EMT; however, the mechanisms associated with this are unclear. We investigated the role of E2 on the expression and intracellular localization of the tight junction (TJ)-associated
proteins, zonula occluden 1 (ZO-1), ZO-1-associated
nucleic acid binding (
ZONAB), and
occludin, on the activation of c-Src and
human epidermal growth factor receptor 2 (HER2) expression and cellular migration in the
estrogen receptor (ER)-positive
breast cancer cell lines, MCF-7 and T47D. We demonstrated that 1 nM E2 elicits c-Src activation after 15 min. The p-Src/ZO-1 complex led to ZO-1 and
ZONAB disruption at the TJ and increased expression of HER2 mRNAs. These changes correlate with decreased expression of the epithelial markers
occludin and CRB3 and increased synthesis of
N-cadherin. This led to increased MCF-7 cell migration induced by E2, even in the presence of a cell proliferation inhibitor. Incubation with
ICI 182,780 (
Fulvestrant), an ER antagonist, precluded the effects of E2 on c-Src phosphorylation, p-Src/ZO-1 complex formation, ZO-1/
ZONAB nuclear translocation, and migration of MCF-7 cells. Our findings suggest that E2 promotes TJ disruption during
tumor progression and increases cell motility. We propose a novel pathway where
estrogens promote EMT-associated mechanisms that possibly lead to
metastasis.